Abstract
Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease characterized by AE resistant to antihistamines and a chronic course. We report five new cases of InH-AAE (two women and three men) with a rapid and dramatic response to the anti-immunoglobulin-E antibody omalizumab. In our literature review, we found 13 other relevant cases with a good response to this treatment. Overall, in 6 out of 18 patients, the doses of omalizumab required to prevent recurrences of attacks were higher than the licensed dose for chronic urticaria. No significant adverse effects have been reported.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53:373–88.
Bork K. Angioedema. Immunol Allergy Clin N Am. 2014;34(1):23–31.
Grattan C, Sabroe R, Greaves M. Chronic urticaria. J Am Acad Dermatol. 2002;46:645–57.
Greaves MW. Pathology and classification of urticaria. Immunol Allergy Clin N Am. 2014;34(1):1–9. doi:10.1016/j.iac.2013.07.009.
Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105(4):664–72.
Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014.
Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015;277(5):585–93.
Zuberbier T, Aberer W, Asero R, BindslevJensen C, Brzoza Z, Canonica G, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87.
Maurer M, Rosen K, Hsieh H, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.
Saini S, Rosen K, Hsieh H, Wong D, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567–573 e561.
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali J, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–9.
Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311–7.
Colas C, Montoiro R, Fraj J, Garces M, Cubero JL, Caballero T. Nonhistaminergic idiopathic angioedema: clinical response to icatibant. J Investig Allergol Clin Immunol. 2012;22:520–1.
Azofra J, Díaz C, Antépara I, Jaúregui I, Soriano A, Ferrer M. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. Ann Allergy Asthma Immunol. 2015;114(5):418–9.e1.
Ozturk AB, Kocaturk E. Omalizumab in recurring larynx angioedema: a case report. Asia Pac Allergy. 2014;4(2):129–30.
Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120(4):979–81.
Shroba J, Hanson J, Portnoy J. Current treatment options for idiopathic angioedema. Ann Allergy Asthma Immunol. 2015;115(5):429–33.
Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol. 2014;178(1):112–7.
Asero R, Tedeschi A, Cugno M. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol. 2010;152:384–9.
Shedden C, Highet AS. Delayed pressure urticaria controlled by tranexamic acid. Clin Exp Dermatol. 2006;31(2):295–6.
von Websky A, Reich K, Steinkraus V, Breuer K. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab. J Dtsch Dermatol Ges. 2013;11(7):677–8.
Muñoz JP, Casado AF, Taboada AC, Campos Muñoz L, Bran EL. Successful treatment of refractory idiopathic angioedema with omalizumab: review of the literature and function of IgE in angioedema. Clin Exp Dermatol. 2015.
Faisant C, Boccon-Gibod I, Mansard C, Dumestre Perard C, Pralong P, Chatain C, et al. Idiopathic histaminergic angioedema without wheals: a case series of 31 patients. Clin Exp Immunol. 2016.
Beck LA, Marcotto GV, MacGlashan Jr D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FceRI expression and function. J Allergy Clin Immunol. 2004;114:527–30.
Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337–42.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Dr Aurélie Du Thanh, Dr Catherine Mansard, Dr Isabelle Boccon-Gibod, and Pr Laurence Bouillet have received financial support from Novartis, France.
Rights and permissions
About this article
Cite this article
Faisant, C., Du Thanh, A., Mansard, C. et al. Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients. J Clin Immunol 37, 80–84 (2017). https://doi.org/10.1007/s10875-016-0345-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-016-0345-7